Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study

Michael W. O'Dell, Allison Brashear, Robert Jech, Thierry Lejeune, Philippe Marque, Djamel Bensmail, Ziyad Ayyoub, David M. Simpson, Magali Volteau, Claire Vilain, Philippe Picaut, Jean Michel Gracies

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited. Objective: To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS. Design: Secondary analysis of a phase 3 study (NCT01313299). Setting: Multicenter, international, double-blind, placebo-controlled clinical trial. Participants: A total of 243 adults with ULS >6 months after stroke or traumatic brain injury, aged 52.8 (13.5) years and 64.3% male, randomized 1:1:1 to receive a single-injection cycle of placebo or abobotulinumtoxinA 500 U or 1000 U (total dose). Methods: The overall effects of injected doses were assessed in the primary analysis, which showed improvement of angles of catch in finger, wrist, and elbow flexors and of active range of motion against these muscle groups. This secondary analysis was performed at each of the possible doses received by finger, wrist, and elbow flexors to establish possible dose effects. Main Outcome Measures: Angle of arrest (XV1) and angle of catch (XV3) were assessed with the Tardieu Scale, and active range of motion (XA). Results: At each muscle group level (finger, wrist, and elbow flexors) improvements in all outcome measures assessed (XV1, XV3, XA) were observed. In each muscle group, increases in abobotulinumtoxinA dose were associated with greater improvements in XV3 and XA, suggesting a dose-dependent effect. Conclusions: Previous clinical trials have established the clinical efficacy of abobotulinumtoxinA by total dose only. The wide range of abobotulinumtoxinA doses per muscle groups used in this study allowed observation of dose-dependent improvements in spasticity and active movement. This information provides a basis for future abobotulinumtoxinA dosing recommendations for health care professionals based on treatment objectives and quantitative assessment of spasticity and active range of motion at individual joints. Level of Evidence: I

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalPM and R
Volume10
Issue number1
DOIs
StatePublished - Jan 2018
Externally publishedYes

Fingerprint

Upper Extremity
Elbow
Articular Range of Motion
Wrist
Fingers
Muscles
Joints
Placebos
Outcome Assessment (Health Care)
Controlled Clinical Trials
abobotulinumtoxinA
Stroke
Observation
Clinical Trials
Delivery of Health Care
Injections

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation
  • Neurology
  • Clinical Neurology

Cite this

Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity : Secondary Analysis of a Phase 3 Study. / O'Dell, Michael W.; Brashear, Allison; Jech, Robert; Lejeune, Thierry; Marque, Philippe; Bensmail, Djamel; Ayyoub, Ziyad; Simpson, David M.; Volteau, Magali; Vilain, Claire; Picaut, Philippe; Gracies, Jean Michel.

In: PM and R, Vol. 10, No. 1, 01.2018, p. 1-10.

Research output: Contribution to journalArticle

O'Dell, MW, Brashear, A, Jech, R, Lejeune, T, Marque, P, Bensmail, D, Ayyoub, Z, Simpson, DM, Volteau, M, Vilain, C, Picaut, P & Gracies, JM 2018, 'Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study', PM and R, vol. 10, no. 1, pp. 1-10. https://doi.org/10.1016/j.pmrj.2017.06.008
O'Dell, Michael W. ; Brashear, Allison ; Jech, Robert ; Lejeune, Thierry ; Marque, Philippe ; Bensmail, Djamel ; Ayyoub, Ziyad ; Simpson, David M. ; Volteau, Magali ; Vilain, Claire ; Picaut, Philippe ; Gracies, Jean Michel. / Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity : Secondary Analysis of a Phase 3 Study. In: PM and R. 2018 ; Vol. 10, No. 1. pp. 1-10.
@article{381fd3c85f674ea1af3d591040ad6970,
title = "Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study",
abstract = "Background: AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited. Objective: To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS. Design: Secondary analysis of a phase 3 study (NCT01313299). Setting: Multicenter, international, double-blind, placebo-controlled clinical trial. Participants: A total of 243 adults with ULS >6 months after stroke or traumatic brain injury, aged 52.8 (13.5) years and 64.3{\%} male, randomized 1:1:1 to receive a single-injection cycle of placebo or abobotulinumtoxinA 500 U or 1000 U (total dose). Methods: The overall effects of injected doses were assessed in the primary analysis, which showed improvement of angles of catch in finger, wrist, and elbow flexors and of active range of motion against these muscle groups. This secondary analysis was performed at each of the possible doses received by finger, wrist, and elbow flexors to establish possible dose effects. Main Outcome Measures: Angle of arrest (XV1) and angle of catch (XV3) were assessed with the Tardieu Scale, and active range of motion (XA). Results: At each muscle group level (finger, wrist, and elbow flexors) improvements in all outcome measures assessed (XV1, XV3, XA) were observed. In each muscle group, increases in abobotulinumtoxinA dose were associated with greater improvements in XV3 and XA, suggesting a dose-dependent effect. Conclusions: Previous clinical trials have established the clinical efficacy of abobotulinumtoxinA by total dose only. The wide range of abobotulinumtoxinA doses per muscle groups used in this study allowed observation of dose-dependent improvements in spasticity and active movement. This information provides a basis for future abobotulinumtoxinA dosing recommendations for health care professionals based on treatment objectives and quantitative assessment of spasticity and active range of motion at individual joints. Level of Evidence: I",
author = "O'Dell, {Michael W.} and Allison Brashear and Robert Jech and Thierry Lejeune and Philippe Marque and Djamel Bensmail and Ziyad Ayyoub and Simpson, {David M.} and Magali Volteau and Claire Vilain and Philippe Picaut and Gracies, {Jean Michel}",
year = "2018",
month = "1",
doi = "10.1016/j.pmrj.2017.06.008",
language = "English (US)",
volume = "10",
pages = "1--10",
journal = "PM and R",
issn = "1934-1482",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity

T2 - Secondary Analysis of a Phase 3 Study

AU - O'Dell, Michael W.

AU - Brashear, Allison

AU - Jech, Robert

AU - Lejeune, Thierry

AU - Marque, Philippe

AU - Bensmail, Djamel

AU - Ayyoub, Ziyad

AU - Simpson, David M.

AU - Volteau, Magali

AU - Vilain, Claire

AU - Picaut, Philippe

AU - Gracies, Jean Michel

PY - 2018/1

Y1 - 2018/1

N2 - Background: AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited. Objective: To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS. Design: Secondary analysis of a phase 3 study (NCT01313299). Setting: Multicenter, international, double-blind, placebo-controlled clinical trial. Participants: A total of 243 adults with ULS >6 months after stroke or traumatic brain injury, aged 52.8 (13.5) years and 64.3% male, randomized 1:1:1 to receive a single-injection cycle of placebo or abobotulinumtoxinA 500 U or 1000 U (total dose). Methods: The overall effects of injected doses were assessed in the primary analysis, which showed improvement of angles of catch in finger, wrist, and elbow flexors and of active range of motion against these muscle groups. This secondary analysis was performed at each of the possible doses received by finger, wrist, and elbow flexors to establish possible dose effects. Main Outcome Measures: Angle of arrest (XV1) and angle of catch (XV3) were assessed with the Tardieu Scale, and active range of motion (XA). Results: At each muscle group level (finger, wrist, and elbow flexors) improvements in all outcome measures assessed (XV1, XV3, XA) were observed. In each muscle group, increases in abobotulinumtoxinA dose were associated with greater improvements in XV3 and XA, suggesting a dose-dependent effect. Conclusions: Previous clinical trials have established the clinical efficacy of abobotulinumtoxinA by total dose only. The wide range of abobotulinumtoxinA doses per muscle groups used in this study allowed observation of dose-dependent improvements in spasticity and active movement. This information provides a basis for future abobotulinumtoxinA dosing recommendations for health care professionals based on treatment objectives and quantitative assessment of spasticity and active range of motion at individual joints. Level of Evidence: I

AB - Background: AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited. Objective: To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS. Design: Secondary analysis of a phase 3 study (NCT01313299). Setting: Multicenter, international, double-blind, placebo-controlled clinical trial. Participants: A total of 243 adults with ULS >6 months after stroke or traumatic brain injury, aged 52.8 (13.5) years and 64.3% male, randomized 1:1:1 to receive a single-injection cycle of placebo or abobotulinumtoxinA 500 U or 1000 U (total dose). Methods: The overall effects of injected doses were assessed in the primary analysis, which showed improvement of angles of catch in finger, wrist, and elbow flexors and of active range of motion against these muscle groups. This secondary analysis was performed at each of the possible doses received by finger, wrist, and elbow flexors to establish possible dose effects. Main Outcome Measures: Angle of arrest (XV1) and angle of catch (XV3) were assessed with the Tardieu Scale, and active range of motion (XA). Results: At each muscle group level (finger, wrist, and elbow flexors) improvements in all outcome measures assessed (XV1, XV3, XA) were observed. In each muscle group, increases in abobotulinumtoxinA dose were associated with greater improvements in XV3 and XA, suggesting a dose-dependent effect. Conclusions: Previous clinical trials have established the clinical efficacy of abobotulinumtoxinA by total dose only. The wide range of abobotulinumtoxinA doses per muscle groups used in this study allowed observation of dose-dependent improvements in spasticity and active movement. This information provides a basis for future abobotulinumtoxinA dosing recommendations for health care professionals based on treatment objectives and quantitative assessment of spasticity and active range of motion at individual joints. Level of Evidence: I

UR - http://www.scopus.com/inward/record.url?scp=85028307300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028307300&partnerID=8YFLogxK

U2 - 10.1016/j.pmrj.2017.06.008

DO - 10.1016/j.pmrj.2017.06.008

M3 - Article

C2 - 28634000

AN - SCOPUS:85028307300

VL - 10

SP - 1

EP - 10

JO - PM and R

JF - PM and R

SN - 1934-1482

IS - 1

ER -